Common adverse events (AE) reported with SGLT2 inhibitor use include increased risk of infections (genital and mycotic) and volume depletion [33]; some of these events are driven by physiological glycosuria induced during SGLT2 inhibitor therapy and may be the impetus for therapy discontinuation in some. The gene discussed is SLC5A2; the disease is infection.